Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
"I’m pretty sure they’ve decided not to tell the market about anything in the diagnostics pipeline ..." I can picture AS standing there arms crossed saying "you can sod off, I'm not saying a bloody word about diagnostics until the deals have been inked"
Mr A AVA6000 may not be suitable for everyone just as Surgery for certain Cancers is not an option. This is sad bad news for those affected but getting hysterical about it and trying to raise fears in investors is pathetic. Go lie down and STFU is my advice.
Unclear what your motivation might be MrA but to be clear MTD will not be found simply because there appears to be no sign of significant Dose Limiting Toxicity. Therefore, the question reduces to what is the Optimal Dose to effect Tumour Regression. This will, I am guessing, be near or below the current dose and the number of cycles will become the focus in Phase 1b.
Yes failure of new drugs is in excess of 90% but AVA6000 is not a new drug and in my judgement the likelyhood of its success must be in the same ball-park, possibly too late but my advice is to buy early to avoid disappointment.
Call me strange but I dont think I would declare on my company web site that I have a product that works only, some weeks later, to declare that it dosent. I know AS has a bit of a history but saying "I know we said it works but it dosent". No chance, ... in my opinion.
I suspect its been mentioned before but anyway on the Avacta website under the Therapeutics/ pre|CISION page there really are no ifs or buts, no question marks, the full nine yards is presented as fact, a done deal. It clearly works:
"Avacta’s proprietary pre|CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAPa) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues. The pre|CISION™ substrate can be utilised in a drug conjugate linker or to generate FAPa-activated chemotherapy – that are only activated in the tumour.
When added to a chemotherapy, the pre|CISION™ substrate prevents the drug from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this FAPa-activated approach, the systemic exposure to the chemotherapy is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments is improved.
Avacta’s long term focus is on achieving a more durable response for patients through synergy of the innate immune response to pre|CISION™ chemotherapies with the adaptive immune response to Affimer® immunotherapies in the form of co-administered combinations and in novel tumour-microenvironment activated drug conjugates
(TMAC®)."
"Winnifrith good on cash and balance sheets" its an analysis many 5 year olds could have made and carefully avoids the many positive aspects that are likely to apply and which all LTHs are well aware of. No LTHs are likely to sell at this point with all the news thats pending. Shouldnt be the case but I wouldnt be surprised if there is something tasty in an RNS tomorrow, but hey ho been wrong before.
"Anybody who ..." you are entitled to your opinion but since you are clearly an idiot please keep such thoughts to yourself. TA is a tool which offers certain insights, it is a lot better than casting runes, on the whole!
Poster presentation Title: AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage Monday Apr 11, 2022 1:30 PM - 5:00 PM CT (18:30 - 22:00 GMT).
Andecc having bought at 271p it must be quite comforting to know that 2500p is a conservative valuation if AVA6000 comes good. Rest assured I and many others feel your pain, quite a way to go for me but curiously the potential here is such that I feel quite relaxed about my 'misplaced cash', a lesson or two learned though thats for sure. Good luck.